What is the current stock price of Structure Therapeutics Inc. (GPCR)?

As of the latest market data, Structure Therapeutics Inc. (GPCR) is trading at $39.54. The stock has seen a loss of -0.10% today.

Does Structure Therapeutics Inc. (GPCR) pay a dividend?

Based on current data, Structure Therapeutics Inc. does not have a confirmed active dividend policy.

What is the market cap of Structure Therapeutics Inc.?

The current market capitalization of Structure Therapeutics Inc. (GPCR) is approximately unavailable.

GPCR

Structure Therapeutics Inc.·Healthcare

39.54

0.101%(−0.04)

Close Price

41.40

4.704%(+1.86)

Pre-Market

Last Updated: — ET

52W L: $15.8052W H: $94.90

GPCR NEWS

globenewswire.com

1d ago

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in two upcoming healthcare conferences in June:

247wallst.com

1d ago

If Viking Therapeutics Is Acquired, Here’s Who Wins

Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX) carries a 38.5% implied probability of being acquired before 2027, with all-time volume above $1.68 million on that single contract. The hook is obesity. Viking's VK2735 dual GLP-1/GIP agonist is arguably the most advanced obesity asset not... If Viking Therapeutics Is Acquired, Here's Who Wins

fool.com

3d ago

This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million

Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.

zacks.com

6d ago

Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?

Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.

fool.com

May 20

Monashee Scales Back Its Bet on Structure Therapeutics

This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.

fool.com

May 17

This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million

This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centered on metabolic and pulmonary targets.

Company Profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

Sector

Healthcare

Industry

Biotechnology

Employees

163

IPO Date

2023-02-03

Beta

-1.39

Websitestructuretx.com↗